A PHASE II MULTICENTER TRIAL OF INTRATUMORAL/INTERSTITIAL THERAPY WITH HN-6600

HN-66000是一种由突变白喉毒素和人类转铁蛋白组成的专利药物配方，正在开发中，作为恶性脑肿瘤的潜在治疗方法。由美国国立卫生研究院赞助的一期试验结果表明，该药物对常规治疗难治的恶性脑肿瘤患者产生肿瘤反应，没有严重的神经或全身毒性。令人鼓舞的结果保证在II期试验中扩大评估。

HN-66000 is a proprietary pharmaceutical formulation of mutant diphthieria toxin and human transferrin that is being developed as a potential treatment for malignant brain tumors. The results from Phase I trial sponsored by the NIH suggest that the drug produces tumor responses in patients with malignant brain tumors refractory to conventional therapy without severe neurologic or systemic toxicity. The encouraging results warrant an expanded evaluation in a phase II trail.